Tovaxin: Interim Phase I/II data

Interim data from a dose-escalation Phase I/II trial showed that Tovaxin was safe and well tolerated. Subjects also saw improvement on the Multiple Sclerosis Impact Scale and the Kurtzke Expanded Disa...